HNSA — Hansa Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK4.77bn
- SEK4.38bn
- SEK222.27m
Brief: Hansa Biopharma: Positive Results From Analysis From NICE-01 Trial Of HNSA-5487
Brief: Hansa Biopharma Q2 Net Income SEK -207.9 Million
Brief: Hansa Biopharma Completes Randomization In Pivotal Phase 3 US Confides Trial
Brief: Hansa Biopharma Completes Randomization In Pivotal Phase 3 Us Confides Trial
Brief: Hansa Biopharma Extends Cash Runway Into 2026
Brief: Hansa Biopharma Q1 Net Income SEK -218.6 Million
Brief: Hansa Bipharma Announces Directed Share Issue Of SEK 372 Mln
Brief: Hansa Biopharma Sees Q1 Revenue Of SEK 54 Mln
Brief: Hansa Biopharma Appoints Evan Ballantyne As CFO
Brief: Hansa Biopharma Q4 Net Income SEK -126.2 Million
Brief: Hansa Biopharma Q4 EBIT SEK -177 Million
Brief: Hansa Biopharma AB Says Imlifidase Met Primary Endpoint In 16-Hmedides-12 Phase 2 Trial
Brief: Hansa Biopharma Announces Positive Results Of Phase 2 Trial Of Drug Imlifidase
Brief: Hansa Biopharma Announces Restructuring Plan
Brief: Hansa Biopharma Announces Planned Departure Of CFO Donato Spota
Brief: Hansa Biopharma Q3 Total Turnover SEK 22.8 Million
Brief: Hansa Biopharma Says Study Shows 90% Patient Survival With Imlifidase
Brief: Hansa Says Total Revenue In Q3 Is SEK 22.8 Million
Brief: Hansa Biopharma Announces Encouraging High-Level Results For First-In-Human Trial Of Hnsa-5487